Under 10% of individuals that would benefit from obesity jabs including Wegovy have access to them, warns the World Health Organization as it issues its initial advice on the therapies.
Given more than one billion people worldwide currently living with obesity, it is advocating for increased and just availability to these injectable treatments.
Based on estimates, over two billion could be obese by 2030 unless action is taken.
"The new guidelines recognises that excess weight is a lifelong illness that can be managed with holistic and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant obstacles to universal availability to the injections that can assist patients in reducing substantial weight, says the body.
Weight-Loss Drug Scarcity
Even under the present best projected case, the supply of GLP-1 therapies might only reach about 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline calls on nations and manufacturers to widen access, by strategies like licensing agreements.
The intellectual property rights on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Injections Function
These medications mimick a natural hormone to reduce digestion speed, reduce hunger and increase satiety so people consume fewer calories.
People usually begin shedding pounds after several weeks of starting on the weekly injections.
Research suggests people may put most of the weight back on a year later of discontinuing the medication, because their typical appetite resume.
Being above a healthy weight increases your risk for experiencing health problems, such as diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the WHO.
